Sanofi, Pfizer, Takeda, or Roche fit partner profile for Amylin's exenatide
This article was originally published in Scrip
Executive Summary
The decision by Amylin and Lilly to end their co-development and marketing deal covering exenatide antidiabetic products potentially opens the door to other partners that might be more committed to driving ex-US sales. The divorce was prompted by Lilly's recent link up with Boehringer Ingelheim for a competing product.